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Abstract
Newly emerging or re-emerging infections continue to pose significant global public health 
threats. This chapter provides an overview of the combinations of factors that led to the 
emergence of arthropod-borne viruses as human and veterinary health threats, in order 
to understand the risk associated and how this can be mitigated. Considering the history 
of emergence of some arboviruses, these epidemics have occurred globally as a result of 
climate and socioeconomic changes that have allowed the spread to new geographical 
areas of viruses previously confined to specific ecological niches such as West Nile and 
Chikungunya, or viruses considered under control such as Dengue, Japanese encephalitis, 
and Yellow fever. Moreover, the greatest risk for humans derives from the ability of these 
viruses to adopt transmission cycles involving highly anthropophilic mosquito species. 
Finally, many other arboviruses are largely ignored despite their potential to emerge glob-
ally. The recent epidemic spread of Zika virus throughout the Americas is the evidence 
that arboviruses are likely to continually emerge and re-emerge and that improved scien-
tific technologies and knowledge is essential to deal with future vector-borne epidemics. 
Research priorities should therefore focus on surveillance systems and vector control tools, 
as well as on the development of antiviral molecules or candidate vaccine.
Keywords: arbovirus, emerging infectious diseases, dengue, Chikungunya, yellow 
fever, West Nile, Zika virus
1. Introduction to arboviruses
Arthropod-borne viruses (arboviruses) are important cause of animal and human disease 
worldwide, infecting millions of individuals and causing a large social and economic burden. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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These viruses are generally transmitted by arthropod vectors to their vertebrate host and 
circulate among wild animals serving as reservoir in sylvatic life cycle. Through spillover 
transmission from enzootic amplification cycles, humans can be infected as incidental and 
dead-end hosts. By contrast, some arboviruses undergo urban cycle involving humans as 
amplifying hosts and causing several epidemics in urban areas [1–3].
By definition, arboviruses require an arthropod vector in the transmission cycle, in which 
they must replicate prior to transmission [1]. Most common arthropods include mosqui-
toes, flies, and ticks along with others hematophagous arthropods [2, 3]. Aedes mosquitoes 
are the most important arboviral vectors; the two main species, Ae. aegypti and Ae. albop­
ictus, allow the transmission of medically important viruses such as chikungunya virus 
(CHIKV), dengue virus (DENV), and yellow fever virus (YFV) [2]. Other prevalent vectors 
are Culex mosquitoes, ticks, sandflies, and Culicoides [4, 5]. Arboviral maintenance and 
amplification cycles involve horizontal, vertical, and venereal transmission. In horizontal 
transmission, the virus is transmitted from an infected vector to a vertebrate host, dur-
ing blood feeding. Following a viremic bloodmeal, virus enters midgut and disseminates 
through the alimentary tract in the vector and replicates in the salivary glands. During 
the following blood feeding, injection of infectious saliva allows the transmission to a 
new host, initiating a new transmission cycle [1, 2, 4]. Many arboviruses are also main-
tained in nature through a secondary cycle that involves vertical transmission from an 
infected female to the offspring. In this case, disseminated virus infects the developing 
eggs, persisting in larval and pupal stages and subsequently into adults. Moreover, vene-
real transmission allows the transfer of virus from a vertically infected male directly to 
a female during copulation [2]. The long-term survival is also enhanced by non-viremic 
transmission, during which infected and noninfected mosquitoes or ticks co-feed on a 
non-viremic host and the virus is transmitted directly between them, without necessarily 
infecting the vertebrate host [2, 4].
Most of the arboviruses that cause human/animal diseases belong to four virus families, 
Togaviridae (genus Alphavirus), Flaviviridae (genus Flavivirus), Bunyaviridae (genera Orthobunya­
virus, Phlebovirus, and Nairovirus), and Reoviridae (genera Coltivirus and Orbivirus) [2, 5]. Infections 
in humans and animals could range from subclinical or mild to encephalic or hemorrhagic with 
a significant proportion of fatalities. In contrast, arthropods infected by arboviruses do not show 
detectable signs of infection, even though the virus may remain in the arthropod for life [4].
A high proportion of arboviruses associated with human and animal disease circulate in 
tropical and subtropical regions, where arthropods tend to be abundant. However, many 
arboviruses also circulate among wildlife species in temperate regions of the world. Despite 
the global distribution of viruses such as West Nile virus (WNV), DENV and now CHIKV, 
most other arboviruses are generally endemic but limited to specific regions of the world. 
Nevertheless, even within this relatively localized distribution, dispersion to distant locations 
can occur via animal or vector migration [4]. Global warming, deforestation, and urbaniza-
tion have led to rapid expansion of the habitats of the vectors and caused enormous increase 
in vector-borne diseases throughout the world. Increase in international travel, shipping, 
and industrialization can lead to transport of infected mosquito and eggs to different new 
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ecological niches facilitating the contact with naïve individuals causing outbreaks of high 
magnitude due to lower herd immunity [2]. The greatest health risk of arboviral emergence 
comes from extensive tropical urbanization and the colonization of this expanding habitat 
by the highly anthropophilic mosquito, Ae. aegypti, together with the recent invasion into the 
Americas, Europe and Africa of Ae. albopictus that could enhance transmission of these viruses 
in temperate regions [1].
More than 500 species of viruses are registered in the International Catalog of Arboviruses 
and this estimate is continuously increasing. While many current arboviruses do not appear 
to be human or animal pathogens, this large number of widely different and highly adapt-
able arboviruses provides an immense resource for the emergence of new pathogens in the 
future [4].
2. Emerging and re-emerging arboviral infections
2.1. Factors associated with arbovirus emergence or invasion
Recent global changes in climate and human behavior are important determinants of arbovi-
rus emergence. The viral transmission can be limited by the ecology of the host or of the virus 
itself; arboviruses frequently persist at low maintenance levels until changes in single or mul-
tiple factors disrupt the transmission cycle, facilitating rapid and widespread amplification 
[1, 6]. Arboviruses can therefore emerge at epidemic levels due to changes in viral genetics, 
in the composition or dynamics of the host or vector population and/or in the environmental 
structure that often are of anthropogenic origin [1].
As arboviruses are virtually all RNA viruses lacking proofreading functions, a high frequency 
of mutations associated with fast replication allows them to rapidly adapt to different envi-
ronments. The high rate of genetic mutations could lead to changes in virulence, epidemi-
ology or competence of vectors, which can occur via simple point mutations [3, 5]. Often, 
outbreaks of emerging arboviruses may be related to relatively small changes in viral genetics 
or to the introduction of new strains that have increased virulence and viremia levels in verte-
brate, thereby expanding the host range and increasing amplification potential. Alternatively, 
genetic changes can improve vector competence and therefore transmission rates [1].
Zoonoses exploiting complex rural or suburban ecosystems may have multiple vectors and 
infect a variety of vertebrate host species. Arboviral amplification can progress rapidly to 
epidemic levels when competent vector and vertebrate host populations meet repeatedly 
within a permissive environment for viral transmission and replication. Moreover, humans 
may be exposed to arboviruses when they invade rural environments or when bridge vectors 
bring viruses into peridomestic environments [1]. Deforestation associated with urbanization 
process has contributed to increase the contact between humans and vectors [7]. Furthermore, 
the expansion of urbanization has led to high concentrations of susceptible human hosts, 
often living in socioeconomic conditions favorable to the expansion of the vector popula-
tion, facilitating viral transmission and outbreaks of epidemics [1]. Furthermore, the feeding 
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preferences (anthropophilic and/or ornithophilic) of arthropod vectors are of fundamental 
importance [8–10]. Arthropods frequently exposed to the human environment, domestic 
animals, and livestock can undertake an adaptive process defined as domestication [8, 11]. 
Moreover, many of the epidemic vectors are peridomestic, naturally existing in close associa-
tion with humans. The vectors of CHIKV, YFV, and Zika virus (ZIKV) all use human habitat 
to maintain their populations [12, 13]; thus, general living conditions along with ineffective 
vector control programs, can contribute to providing one component necessary for arboviral 
transmission [5, 7].
Changes in the composition of vertebrate or vector host species may be related to environmen-
tal changes that expand old or create new ecological niches. Extensions of the vector range 
into permissive environments are often followed by invasion of the arboviruses they transmit. 
These invasions are generally facilitated by travel and commerce [1], constantly introducing 
new species of viruses and their arthropod vectors into new geographic areas. Most of these 
introductions are not detected until they cause an epidemic, when they are already well estab-
lished and it is not possible to eliminate them from the new area [7]. An additional factor that 
plays a role in the generation of arboviral outbreaks is the immunity status of vertebrate hosts 
in the affected areas. Outbreaks registered for the first time in a new area usually involve 
immunologically naïve populations, exhibiting extremely high rates of attack. Even in areas 
where epidemics have previously occurred, rare epidemic events interspersed with signifi-
cant interepidemic periods may render the younger generation susceptible to infection [5].
Following their recent local and global emergence, some arboviruses have acquired great 
importance in terms of public and veterinary health. The combinations of factors that led to 
their emergence are of fundamental importance to understand the risk associated and how 
this can be mitigated. Moreover, many other arboviruses are largely ignored despite their 
potential to emerge globally [1].
2.2. Emerging and re-emerging arboviruses
2.2.1. Dengue virus
DENV (Flaviviridae: Flavivirus) is the only arbovirus that has completely evolved and adapted 
to the human host and its environment, eliminating the need of other animal reservoirs. There 
are four DENV strains, referred to as DENV1–4 serotypes, antigenically distinct but with the 
same epidemiology and symptomatology in humans. Generally, DENV is associated with 
mild clinical manifestations during interepidemic periods, but it can cause epidemics associ-
ated with a more severe disease every 3–5 years. Co-circulation of multiple serotypes (hyper-
endemia) is the most common risk factor associated with the emergence of the severe form 
of the disease, dengue hemorrhagic fever/shock syndrome (DHF/DSS), in an area [7]. Relying 
exclusively on humans as reservoir and amplification hosts, the maintenance of DENV is 
based on transmission by mosquito vectors living in close association with humans [1]. The 
main vector in urban environments is Ae. aegypti, however DENV can also be transmitted 
by Ae. albopictus in suburban, rural, and forest areas in tropical, subtropical, and temperate 
regions of the world where it is widely present [8, 13]. DENV is the geographically most wide-
spread arbovirus and the most serious arboviral threat, showing high levels of endemic trans-
mission in the Americas, south-east Asia and the western Pacific, with about 4 billion people 
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at risk of infection [14]. Moreover, DENV is hyperendemic in many Asian tropical regions, 
where two or more serotypes circulate both endemically and epidemically [1]. A total of 390 
million infections, of which about 100 million symptomatic, are estimated each year, with 
several hundred thousand cases of DHF and thousands of deaths [15, 16]. The resurgence 
of DENV has been stimulated by population growth and density, urbanization and interna-
tional travels, as well as changes in environmental conditions, prevalence of vectors and virus 
genetics. The resulting geographic expansion has been accompanied by exponential increases 
in cases, epidemics, and co-circulation of different serotypes. In particular, hyperendemicity 
in many areas of tropics and subtropics is due to serotype dispersal derived from large-scale 
human movements, which together with levels of preexisting immunity of the herd to specific 
viral serotypes have led to an increase of DHF epidemics [17, 18]. Moreover, introduction of 
DENV has occurred several times in temperate or subtropical climate zones in recent years. 
By 2010, autochthonous cases of DENV infection were identified in Europe, and in October 
2012, Madeira recorded a major DENV outbreak, with over 2100 cases by March 2013 [19–21]. 
Furthermore, the repeated episodes of DENV local transmission (Hawaii in 2001–2002, Texas 
in 2005, and Florida in 2009–2011) and the wide distribution of Ae. aegypti and Ae. albopictus 
in the USA underscores the importance of surveillance and vector control in areas at risk of 
DENV introduction [22–24].
2.2.2. Chikungunya virus
CHIKV is an Alphavirus of the Togaviridae family that circulates in enzootic cycles among 
nonhuman primates with multiple Aedes mosquitoes implicated as vectors, with Ae. aegypti 
identified as the main human vector [25]. Historically, CHIKV has been considered a highly 
debilitating but not life-threatening pathogen, whose infection is associated with fever, 
headache, myalgia, rash, and severe arthralgia. Because these symptoms often mimic those 
of DENV and because CHIKV circulates in DENV-endemic regions, CHIKV has long been 
underdiagnosed and underestimated as an important arboviral disease [1]. In Southeast 
Asia, CHIKV was recognized as the etiologic cause of febrile disease epidemics in the 1950s 
and continues to be an important pathogen [26]. Unlike in Africa, where there is evidence 
of a sylvatic cycle involving arboreal mosquitoes and nonhuman primates, CHIKV appears 
to be maintained in Asia in a strictly human-peridomestic cycle of mosquitoes [1]. CHIKV 
has re-emerged in 2005 in a succession of massive outbreaks in East Africa and the Southern 
Indian Ocean Islands [5]. The first major outbreak occurred in Kenya during 2004, followed 
by a large outbreak on La Réunion Island in 2005–2006 [6]. The genetic characterization 
indicated that the epidemic strain originated from the East/Central/South African (ECSA) 
lineage, but the outbreak of La Réunion was associated with a mutation on the viral enve-
lope glycoproteins enabling more effective transmission by Ae. albopictus [6, 27, 28]. This new 
lineage, called Indian Ocean Lineage (IOL), spread quickly across the Indian Ocean Basin, 
India, and Southeast Asia. Moreover, infected travelers imported it into Europe, with two 
small outbreaks occurring in northern Italy and southern France [29–31]. Between late 2013 
and beginning of 2014, autochthonous cases of CHIKV were reported in the Caribbean. The 
strain implicated belonged to the Asian strain, identified in the late 1950s in Southeast Asian 
countries [32]. Finally, a distinct East/Central/south African strain (ECSA) spread directly to 
Brazil in 2014 [33]. During these massive outbreaks of CHIKV, also the clinical presentation 
appeared to be evolving as well, with neurological manifestations and mortality. Moreover, 
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maternal infection was observed to be vertically transmitted, most commonly during birth, 
leading to severe disease and encephalopathy in half of neonates and resulting in long-term 
neurologic sequelae [34].
2.2.3. Zika virus
ZIKV (Flaviviridae: Flavivirus) is primarily transmitted by mosquitoes of Aedes genus, includ-
ing not only Ae. aegypti for urban transmission but also Ae. albopictus, Ae. poliniensis, and 
Ae. hensilli. Recently, transmission of the virus has also been reported via sexual, neonatal, 
and blood transfusion. ZIKV infection can be asymptomatic or cause a mild febrile illness 
characterized by headaches, myalgia, fever, rash, and conjunctivitis [35]. ZIKV was isolated 
and associated with human disease more than 60 years ago, but remained poorly studied 
until an association with neurological involvement was observed. In fact, an increase in the 
incidence of cases of Guillain-Barré syndrome and microcephaly in neonates was observed 
in regions with an ongoing ZIKV epidemic [35, 36]. The first major outbreak of ZIKV was 
reported outside Africa in 2007 in Micronesia [37, 38], followed by a second major outbreak 
in French Polynesia in 2013 [39]. The largest ZIKV outbreak began in Brazil at the end of 2014 
with 1.3 million cases estimated by the end of 2015. In May 2016, 47 countries and territories 
in the Americas, including the USA, reported autochthonous cases of ZIKV [6]. The impact of 
ZIKV infections on the development of the central nervous system will be defined only in the 
years to come; at present, the degree of developmental delay or other neurological sequelae 
that could have babies born to mothers affected by ZIKV is not known. Another important 
aspect of the future epidemiology of ZIKV infections is the possibility of blood transmission 
and the consequent need for blood testing in high-incidence areas [35]. In 2017, the number of 
reported cases that decreased dramatically in Brazil and other American countries, maybe due 
to the high number of infected people who have acquired protective immunity to reinfection 
and improved vector control strategies in countries where an epidemic has been reported. 
However, now the epidemic is no longer considered an international medical emergency and 
there may be a sharp decline in investment in research and control related to ZIKV. Although 
the number of ZIKV cases has declined, the risk of another major epidemic in Brazil and other 
tropical and subtropical countries is still significant and its intensity is difficult to predict. It 
is therefore essential to develop systems that allow a more accurate diagnosis of ZIKV infec-
tions to differentiate it from other flavivirus infections, in particular by using serological tests 
that can be performed in any developing country. Furthermore, the development of a safe 
vaccine is of paramount importance for the containment of ZIKV infection, in particular for 
immunocompromised and pregnant women, but the adverse effects in the development of 
Guillain-Barré syndrome and the enhancement of other flavivirus diseases by antibodies pro-
duced against ZIKV, in particular, toward a future DENV infection must be considered [35].
2.2.4. Yellow fever virus
YFV is the type of species in the Flavivirus genus of the family Flaviviridae. The primary 
transmission cycle occurs between nonhuman primates and a range of arboreal mosquito 
species mainly belonging to the genera Aedes and Haemagogus, in Africa and South America, 
respectively. Transmission to humans occurs as the result of frequent spillover events in the 
so-called zone of emergence, where the presence of Ae. aegypti as primary peridomestic vector 
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can initiate an urban cycle characterized by rapid human-mosquito transmission that leads 
to explosive outbreaks [40, 41]. The epidemiology of YFV in Africa often involves both syl-
vatic and urban cycles increasing the force of infection during human epidemics, that result 
larger than in South America [40]. In humans, YF is a severe acute illness with fever, nausea, 
hepatitis with jaundice, renal failure, hemorrhage, and shock with case fatality lower in Africa 
(20%) than in south America (40–60%) [42], suggesting a correlation between genetic factors 
and lethality of the infection. In Africa as well as in South America, high YF case rates likely 
occur due to low vaccination coverage in area of endemic transmission. According to WHO 
and the United Nations Children’s Emergency Fund (UNICEF) estimates, only 41% of the 
target population had received YF vaccination in 2014, well below the recommended 80% 
threshold for the prevention of an epidemic [41]. However, the underlying reasons for virus 
amplification could be multifactorial, including the possibility of a new virus lineage emerg-
ing correlating with the expansion of YFV activity [43]. In endemic areas, deforestation has 
been associated with emergence of YF outbreaks due to the higher biting activity of vectors, 
especially in new settlements inside or near the forest frequently colonized by unvaccinated 
migrant populations. Moreover, perturbation in environmental conditions, such as increase 
in rainfall and temperatures, has been associated with an abundance of vectors enhanc-
ing YFV circulation with increased outbreaks in Africa and South America [40]. YFV could 
potentially emerge and disperse in a similar manner to DENV, CHIKV, and ZIKV in South 
America. The recent outbreak of YF in Brazil and multiple reports of cases outside endemic 
regions highlight the possibility of urban YF arising [8]. In fact, many cases were reported 
in areas considered free of virus circulation, where routine YF vaccination is not performed. 
A molecular study showed implicated a new YFV lineage which evolved from the lineage 
circulating in Brazil in the 1990s, and moved toward the Atlantic coast, the most populated 
area in Brazil [40]. Moreover, YFV could become the next arbovirus to emerge as a public 
health emergency if swift to international spread occurs. Since December 2015, YF epidemic 
has been reported in Angola, spreading to Kenya and the Democratic Republic of the Congo. 
Moreover, in April 2016, YFV was exported to China via unvaccinated workers, representing 
the first laboratory-documented cases of YFV in Asia [41]. This risk is particularly acute in the 
Asia-Pacific region, where systems for YFV surveillance and detection are largely untested 
and YF vaccination is limited to travelers [44]. If introduction of YFV occurs in areas with a 
high density of Ae. aegypti, it is possible that local transmission could occur and potentially 
spread to Southeast Asia, putting approximately 2 billion people at risk without there being 
sufficient vaccine stockpiles [41].
2.2.5. West Nile virus
WNV belongs to the Japanese encephalitis virus (JEV) serocomplex in the genus Flavivirus. 
It is maintained in nature within an enzootic transmission cycle among birds and Culex mos-
quitoes, with outbreaks caused by spillover transmission to equids and humans, which are 
dead-end hosts [1]. Based on serological evidences, WNV circulates in the absence of clini-
cal disease in the majority of humans and a wide variety of different animal species, but in 
abundancy of Culex species mosquitoes WNV, may also cause epidemics with disease symp-
toms ranging from subclinical or mild febrile to encephalic with or without flaccid paralysis 
and fatality [8, 10]. WNV is distributed globally, with two main genetic lineages: Lineage 
1 is widely distributed and highly invasive, whereas Lineage 2 appears to have remained 
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enzootic in Africa. Lineage 3 and 4 have been described from single isolates in Central Europe, 
whereas Lineage 5 appears to be confined to India [45]. International dispersal of Cx. pipiens  
mosquitoes that appear to be closely associated with human infection and urban outbreaks, 
and the introduction of the house sparrow (Passer domesticus) as a highly competent host 
for most WNV strains, has provided the availability of maintenance and amplification 
cycle of the virus almost circumglobally. Moreover, climate changes at northern temperate 
latitudes, recently, have made these areas more conducive to WNV invasion [1]. Outbreaks 
of WNV were recorded throughout the Mediterranean basin, Central Europe, and Russia, 
where Cx. pipiens appeared to be the primary vector. In the Americas, WNV was introduced 
into New York during the summer of 1999. Phylogenetic evidence suggest that the invad-
ing strain was closely related to a 1998 isolate from Israel that contained a mutation causing 
high viremia and mortality in American crows and higher transmission competence of Culex 
mosquito species. Once the virus had been introduced in the USA, migratory birds played a 
major role in the dispersal of WNV throughout North America [1, 10]. WNV is now one of 
the most broadly distributed arboviruses in the world, as well as the most common cause of 
arboviral neuroinvasive disease in the USA [1, 5]. Currently, WNV vaccines are only available 
for equids, although human vaccines are under development [6]. However, the motivation 
for human vaccine development may be limited by the low attack rate that the virus exhibits 
in humans following epidemics. Therefore, in the near term, protection for public health will 
continue to rely on mosquito control [1].
2.2.6. Japanese encephalitis virus
JEV is the most frequent cause of mosquito-borne encephalitis globally. The public health sig-
nificance and the global distribution of JEV have been progressively expanding; currently, more 
than 3 billion people in Asia reside in areas at risk of JE, with an estimated 50,000 symptomatic 
cases and 10,000 deaths occurring annually [46]. Taxonomically, JEV is placed within the genus 
Flavivirus and is the type of virus for the JEV serocomplex. JEV is maintained within an aquatic 
bird-Culex mosquito transmission cycle and is amplified within a domestic swine-Culex cycle. 
Moreover, Culex mosquitoes can transmit JEV to equids and humans, which are dead-end hosts 
for the virus. JEV is endemic in large parts of Asia and the Pacific, where mosquito vectors 
are present in association with rice and other irrigated crops [1, 46]. Of the five major genetic 
lineages, lineages 1 and 3 have been found co-circulating in subtropical and temperate latitudes 
and are associated with outbreaks of neuroinvasive disease. However, lineage 5 now appears 
to be emerging as the predominant genotype. The epidemiological significance is bounded to 
the fact that lineage 5 is antigenically the most diverse genotype and the current JEV vaccine 
shows limited efficacy against this genotype [8, 47]. Moreover, the primary mosquito vector, 
Culex tritaeniorhynchus, has been recently identified in north western Greece [48] and JEV RNA 
was detected in Cx. Pipiens mosquitoes in Italy [49], thus potentially increasing the risk of JEV 
emergence in Europe. In addition, the even more recent detection of autochthonous JEV co-
infection during the YF outbreak in Angola [50] supports the idea that JEV may have already 
expanded its Asian boundaries [8]. The rapid and widespread expansion of JEV in the Asian 
continent was associated closely with increases in human populations, in acreage of irrigated 
rice and pig farming. In endemic areas of Japan, the avian-Culex maintenance cycle may be 
bypassed when vertically infected Cx. tritaeniorhynchus directly initiate the amplification cycle 
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in pigs [1]. The risk that JEV becomes a greater threat in the near future is quite high, given the 
genetic diversity of the virus and several Aedes species as marginal competent vectors [6]. Air 
transport of mosquitoes was the probable cause of JEV outbreaks on isolated Pacific Islands, 
demonstrating the potential of this virus to invade new areas such as the west coast of the 
USA. Moreover, with the spread of JEV into much of the Indian subcontinent, other destina-
tions served by frequent routes of commerce or passenger air travel, such as Africa and Europe, 
also could be at risk [1].
2.3. Arboviruses with potential of emergence
2.3.1. Rift Valley fever virus
Rift Valley fever virus (RVFV) is classified within the genus Phlebovirus in the family Bunyaviridae 
and circulates in Central West, East and South Africa and in the Arabian Peninsula [8, 51]. 
Infection causes severe and often fatal illness in sheep, cattle, goats and camels, with occasional 
spillover to humans, in which the infection shows no symptoms or a mild illness associated 
with fever and liver abnormalities [1, 8]. However, during RVFV epizootics, up to 10% of 
affected humans may develop more severe disease, including encephalitis, retinitis, and hem-
orrhagic fever with case fatality rate approximately 10–20% [8, 52]. RVFV is maintained in an 
enzootic cycle among wildlife and a wide variety of mosquito species, including Aedes, Culex, 
Anopheles, and Mansonia. The virus is maintained by vertical transmission in eggs of Aedes 
species during dry season, with intermittent epizootic outbreaks occur during rainy season 
[1, 8]. Historically, RVFV was restricted to sub-Saharan eastern Africa, especially Rift Valley 
of the Kenya and Tanzania. Subsequent outbreaks with human involvement have been docu-
mented in South Africa, the Nile Valley, and the Saudi Arabian Peninsula. A large outbreak in 
Mauritania indicated dispersal of the virus in West Africa [53, 54], demonstrating the ability of 
RVFV to escape historical enzootic areas. Major irrigation projects and the El Nino effect are 
considered to be the important factors influencing the epidemiology of RVFV [4, 55] and the 
movement of viremic camels along trade routes that has been suspected to be the routes of 
dispersal. Moreover, before the onset of the disease, humans develop viremias suitable to infect 
susceptible mosquitoes; uncontrolled air travel therefore could introduce RVFV into North 
America or Europe where susceptible wild and domestic hosts and suitable vectors reside [1, 
56]. RVFV is generally considered to be a candidate for emergence and global dispersion but, as 
the virus is transmissible by a wide variety of mosquitoes adapted to the local habitats in Africa 
and Ae. Aegypti is not a recognized primary vector, the likelihood of expansion outside Africa 
and Saudi Arabia appears to be low. However, RVFV could be inadvertently introduced via 
infected mosquitoes into a tropical region where competent domestic Ae. aegypti predominate 
in the urban environment [8]. Nevertheless, laboratory infection has highlighted the presence 
of competent Cx. Pipiens in Southern France and Tunisia with the potential for RVFV epizootics 
to occur in the virus, which was introduced into countries of the Mediterranean basin [57]. 
Several vaccines for RVFV have been developed and appear effective; however, their use is 
limited. Failure to contain these outbreaks provides a source of virus to seed outbreaks into 
other areas of Africa and the Middle East as well as the rest of the world. With a high potential 
impact on wildlife, domestic animal, and human health, failure to contain RVFV could seri-
ously impact veterinary and human health in Asia, Europe, and the Americas [1, 51].




Mayaro virus (MAYV) is an emerging alphavirus with autochthonous transmission in central 
and south America with higher prevalence in amazon region; recently, it has been reported 
to circulate in the Caribbean [58, 59]. Infection produces indistinguishable symptoms to the 
closely related CHIKV; therefore, due to the high degree of co-circulation with CHIKV, DENV, 
and similar viruses, cases of MAYV infection are not reported frequently. An estimated 1% of 
all febrile dengue-like illness in northern South America is caused by MAYV, as evidenced by 
the high rates of detection during regional serosurveillance [6, 60, 61]. The transmission cycle 
of MAYV is similar to the sylvatic transmission of YFV, with nonhuman primates as main res-
ervoirs. The primary vectors are likely mosquitoes from the genus Haemagogus; however, the 
virus has also been detected in other mosquitoes and mites [1]. A major concern is that MAYV 
has also been detected in two of the most abundant mosquito genera: Culex and Aedes [6, 62]. 
Experimental evidence suggests that the virus is highly infectious to Ae. aegypti [63] and can 
be transmitted at low rates by Ae. albopictus, making that species a potential secondary vector 
[6, 64]. Historically, MAYV outbreaks have been sporadic, however, spillover events have 
occurred following deforestation and urbanization in endemic areas, both of which bring the 
virus into closer proximity to larger human populations, and to their associated urban vectors 
[1, 6, 65]. Given the close genetic relationship with CHIKV, it is plausible that MAYV could 
also evolve to become more infectious to humans or anthropophilic mosquitoes, and experi-
ence similarly high levels of outbreaks.
2.3.3. Venezuelan equine encephalitis virus
Venezuelan equine encephalitis virus (VEEV) is an alphavirus (Togaviridae: Alphavirus) widely 
distributed in tropical and subtropical regions of the Americas, where it circulates endemically 
between mosquitoes of the genus Culex and rodents. The VEEV complex can be subdivided 
into six different subtypes (I to IV) with type I further divided into other antigenic variants; 
only VEEV subtypes IAB and IC are considered epizootic variants and are pathogenic for 
horses [66, 67]. Also humans infected with epidemic VEEV strains develop high titers viremia 
and may therefore play a role as maintenance and amplification hosts [67–69]. Main epidem-
ics occur when VEEV epidemic strains spill over into competent mosquitoes of the genera 
Aedes and Psorophora, which have a peridomestic behavior and may transmit VEEV to equids. 
An equine-mosquito amplification cycle may induce an extensive virus circulation that may 
spill over to humans and cause outbreaks of VEEV. Epidemic VEEV infection in humans is a 
highly disabling dengue-like febrile disease, which can lead to severe encephalitis with fatality 
rates of between 1 and 3%, especially in children [67, 70]. Moreover, if infection occurs during 
pregnancy, it may lead to severe neurological birth defects and anomalies [66]. The emergence 
of VEEV epidemics is based on a combination of ecological and viral genetic factors. Enzootic 
VEEV strains are not able to achieve a sufficient viremia for equine amplification. However, 
a single mutation in the viral genome can lead to changes in the viral envelope improving 
equine amplification. Because alphaviruses replicate with low genetic fidelity, it is likely that 
mutations competent for equine amplification occur regularly within sylvatic cycles. Then, 
the transport of mutants strains competent for the equine amplification in areas with sus-
ceptible equids and mosquito vectors allows the emergence of epidemics [1]. The last major 
VEE epidemic, which involved ca. 100,000 persons with an estimated 300 deaths, occurred in 
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Venezuela and Colombia in 1995 [71, 72]. In these areas, natural emergence will occur periodi-
cally, as long as equine herd immunity is not maintained at adequate levels by vaccination 
or natural acquisition of immunity from enzootic exposure. The risk of epidemic emergence 
may be increasing by the conversion of large areas of tropical forest to ranching and other 
forms of agriculture, increasing opportunities for infection of bridge vectors competent to the 
generation of an equine amplified cycle. Furthermore, urban peridomestic mosquito vectors 
such as Ae. aegypti [73] and Ae. albopictus [74] are capable of transmission after oral doses com-
parable to human viremia titers, making an Ae. aegypti-borne epidemic VEEV cycle possible 
[1]. Prevention and control of epizootic/epidemic VEEV depends on effective use of veterinary 
vaccines, but equine vaccination in many countries is not widespread. Therefore, during epi-
zootic/epidemic transmission, mosquito control is an important adjunct to vaccination [7].
3. Strategies for arbovirus control
Because they are not an essential part in the zoonotic arbovirus life cycle, arbovirus disease 
control based on humans and domestic animals cannot eradicate the arbovirus. Consequently, 
the reservoir in wild species places a limitation in the control disease emergence, and only 
understanding the interactions involved in the biology of the virus, hosts, and ecology will 
lead to effective control and prevention strategies [4, 5]. With effective vaccination and sustain-
able vector control programs, it is possible to control or even eliminate human transmission 
cycles. In fact, vaccination can increase herd immunity, making it easier to sustain reduced 
virus transmission with vector control. On the other hand, vector control can complement a 
vaccine by lowering the risk of infection, making vaccine delivery goals easier to achieve [75].
The YF vaccine has been used extensively in West Africa and has been instrumental in 
eliminating the urban transmission cycle in South America. However, despite its efficacy and 
low-cost production, epidemics continue to occur due to inadequate vaccination coverage, as 
demonstrated by the recent YF outbreak in Angola and Democratic Republic of Congo [76]. 
Adequate and continuous vaccination programs along with high levels of herd immunity are 
of paramount importance for the control of YF. In Africa, together with childhood immuniza-
tion, mass preventive vaccination campaigns to protect elderly people need to be implemented 
[77]. Moreover, in South America, people of coastal areas are largely unvaccinated and there-
fore exposed to the risk of YFV coming from the near enzootic regions [75]. Finally, YF cases 
reported from travelers from Angola to China highlight the need to implement the WHO 
International Health Regulations in order to protect travelers and to avoid the introduction of 
YFV in naïve areas of Asia where the vector is widely present [76]. Japanese encephalitis was 
controlled in Japan, Taiwan, and Korea using inactivated vaccines, which also contributed to 
control infection in China [10, 78]. A live attenuated JEV vaccine was used to reduce the risk 
of infection in children in China, as well as being part of the large children immunization 
campaign in India [10]. At the end of 2015, the first dengue vaccine was licensed (CYD-TDV 
vaccine Dengvaxia). The results of a large phase III study in 10 endemic countries in Asia 
and South America showed a complex performance of the vaccine with efficacy dependent 
on serotype, as well as previous immunity and age of the subject [79, 80]. Two other live 
dengue virus vaccines are in phase III trials and many other dengue vaccines are in phase 
I and II trials [75]. Research on vaccines against CHIKV has been slow, as CHIKV causes 
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major epidemics only every 10–30 years, limiting the interest of the pharmaceutical industry 
for a financial return [75]. However, two vaccines against CHIKV have recently completed 
phase I clinical trials, both are strongly immunogenic after 2–3 doses and are currently in 
phase II trials [81, 82]. Among more than 40 Zika vaccines developed, DNA, RNA, and inac-
tivated virus [83–85] versions started clinical trials and the first live-attenuated vaccine has 
been demonstrated to be safe and efficacious after a single dose in mice [86]. However, there 
are some concerns about potential interactions with immunity generated by other flavivirus 
natural infections or vaccines leading to more severe manifestations of the disease, as well as 
the immune trigger in the development of Guillain-Barre syndrome [87]. Currently, there is 
no specific licensed anti-arbovirus agent, and patient management is therefore mainly sup-
portive. Passive immunotherapy is a promising approach for the management of newborns 
exposed to CHIKV. The anti-CHIKV human immunoglobulins purified from convalescent 
donors exhibit strong anti-CHIKV effects in vitro and animal models [88], and are now evalu-
ated in the prevention of mother-to-child CHIKV transmission in newborns born to viremic 
mothers [87]. Novel antiviral therapies are also being investigated. Drug repurposing strate-
gies have identified potential inhibitors of Flaviviridae replication. Ivermectin strongly inhibits 
the replication of YFV, DENV, and WNV [89], while azithromycin inhibits the cytopathic 
effects induced by ZIKV in glial lines and in human astrocytes and is also considered safe for 
use during pregnancy [90]. Further new approaches aim to identify host factors and pathways 
that are critical for viral replication and to identify the putative inhibitors of these pathways 
as host-targeting antivirals [87].
The continued outbreaks of YFV and JEV demonstrate that even with a widely available and 
effective vaccine, it is difficult to control a vector-borne disease using only vaccination [6]. 
Overall, the best current perspectives for controlling the majority of vector-borne diseases rely 
on reducing the contact between the vector and susceptible humans and the most effective 
approach for this goal remains the elimination or reduction of mosquito populations [87]. 
Nowadays, many of the insecticides used in the mid-twentieth century eradication campaign 
are considered environmentally unacceptable, as well as being economically prohibitive 
and at risk of developing resistance in mosquito populations [87, 91]. Several alternative 
approaches are focused on reducing the abundance of mosquitoes or preventing the trans-
mission of pathogens by the mosquito. Environmental management includes modification of 
the natural breeding habitat of mosquitoes and the adoption of human behaviors that reduce 
the incidence of the bite, such as the elimination of domestic oviposition and larval sites, the 
indoor residual spraying and fumigation, the use of insecticide-treated bed nets and screen-
ing windows together with lethal traps, which have been found to be effective in reducing 
Ae. aegypti populations and transmission of CHIKV and DENV [87, 91, 92]. Another approach 
involves genetic modification of vectors and the release of genetically modified male mosqui-
toes expressing a dominant lethal gene, determining the death of all progeny from mating 
with wild females (sterile insect technique, SIT) [87, 91, 93]. Moreover, also the vector compe-
tence can be reduced by limiting viral infection or transmission through the introduction of 
transgenic mosquito lines in the field [94, 95]. Biological control represents another possible 
intervention and includes the use of natural predators or pathogens against mosquitoes. The 
strategy that involves the release of mosquitoes infected by Wolbachia pipientis, an endosymbi-
ont bacterium that is transmitted vertically, allows to suppress the viral transmission by inter-
fering with the reproduction of the mosquitoes [6, 87, 91]. Wolbachia infection affects sperm 
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preventing successful reproduction between infected and uninfected males and between 
infected males and females harboring different strains of Wolbachia, similar in method and effect 
to SIT [91, 96]. Wolbachia can also be used as a population replacement strategy, which consists 
in the release of female mosquitoes infected by Wolbachia, relying on high levels of maternal 
transmission [97]. The introduction of Wolbachia in the naturally uninfected field Ae. aegypti  
populations is currently used to confer resistance to viral infection, making infected mosqui-
toes poor vectors of pathogens of medical importance including DENV and CHIKV [98, 99] 
with similar effects characterized recently against ZIKV [100, 101].
The implementation of localized arthropod control measures during epidemics, for example, 
in high-density urbanized areas, can play an important but transient role in reducing the 
impact on humans and animals of emerging arboviruses if these are supported from surveil-
lance systems, which differ at regional level and in many areas are completely absent [4]. 
Furthermore, it is essential to characterize and understand viral genetics, antigenic properties, 
virulence patterns, vector associations, and maintenance mechanisms to identify and control 
future arboviral outbreaks. The next public health needs include communication to the popu-
lation and physicians of vector-borne diseases, the guarantee of vector control programs, and 
the maintenance of adequate surveillance systems with trained personnel, together with the 
availability of drugs, vaccines, and rapid diagnostic testing [5].
4. Conclusions
Arboviruses already have a well-known history of emergence and will undoubtedly continue 
to emerge in the future. There are many unidentified arboviruses that, due to their high muta-
tion rates, may emerge as pathogens even if they are not yet present as epidemic strains in 
the wild environment. Recent progress in sequencing offers new opportunities to identify 
them during surveillance activities, especially in the tropics, where viral diversity is higher 
[3]. The greatest risk for humans derives from the ability of some arboviruses to adopt urban 
transmission cycles involving highly efficient and anthropophilic vectors, such as Ae. aegypti 
and Ae. albopictus, or enzootic peridomestic cycles involving Culex urban populations [1]. The 
ability to urbanize and cause an epidemic, exemplified by DENV, CHIKV, and YFV, could 
be acquired by many other viruses, including VEEV and MAYV, which have the potential to 
infect these urban vectors and whose exposure to urban populations in the tropics is already 
known. A more complete understanding of the molecular interactions associated with the 
emergence will be particularly useful in predicting the likelihood of this happening [3]. The 
public health emergency of ZIKV, the threat of the YF, and the re-emergence of DENV and 
CHIKV should serve as a wake-up call for governments, academics, and WHO to strengthen 
the control and research programs on arboviral infections [75]. A continuous international 
and interdisciplinary response is needed to improve the ability to anticipate, control, and 
mitigate the risk of emerging and re-emerging arboviruses. Research priorities should focus 
on surveillance systems, knowledge of factors responsible for adaptation to other vectors, and 
other determinants of infection and transmission, as well as on the development of antiviral 
molecules or candidate vaccine. The shared characteristics of these viruses could stimulate 
common research themes for the development of antiviral therapies and vaccines, while the 
co-circulation of these viruses requires the development of differential diagnostic systems, 
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including more specific serological tests for seroprevalence studies. The socioeconomic and 
environmental factors driving the proliferation of vectors, particularly in cities of low-income 
countries, must be mitigated. An assessment of the available and developing vector control 
tools is needed to identify the most effective techniques and their combination with vaccina-
tion. Finally, new global alliances are needed, such as the global Dengue and the Aedes-related 
disease consortium, to enable the combination of the most effective and timely solutions 
against arboviral diseases [75].
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